Fibroblast growth factor 21 improves insulin sensitivity and synergizes with insulin in human adipose stem cell-Derived (hASC) adipocytes

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Lee, Darwin V ^a   Li, Dongmei ^a   Yan, Qingyun ^a   Zhu, Yimin ^a   Goodwin, Bryan ^a   Calle, Roberto ^a   Brenner, Martin B ^a,b   Talukdar, Saswata ^a  

^a PFIZER INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DEOXYGLUCOSE; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; PROTEIN KINASE B; SERINE; SOMATOMEDIN C RECEPTOR; TYROSINE; FIBROBLAST GROWTH FACTOR; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN;

ADIPOCYTE; ADIPOSE DERIVED STEM CELL; ARTICLE; CONCENTRATION RESPONSE; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG POTENTIATION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INSULIN SENSITIVITY; METABOLIC ACTIVATION; MONOTHERAPY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ADIPOSE TISSUE; AGONISTS; CELL CULTURE; DRUG EFFECTS; INSULIN RESISTANCE; METABOLISM; STEM CELL;

ADIPOCYTES; ADIPOSE TISSUE; CELLS, CULTURED; DRUG SYNERGISM; FIBROBLAST GROWTH FACTORS; GLUCOSE; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 84909646839     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111767     Document Type: Article

References (33)

1. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627-1635.
2. Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, et al. (2010) Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24:2050-2064.
3. Kliewer SA, Mangelsdorf DJ (2010) Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 91:254S-257S.
4. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250-259.
5. Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, et al. (2013) Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One 8:e58575.
6. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018-6027.
7. Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, et al. (2013) Development of a Novel Long-Acting Antidiabetic FGF21 Mimetic by Targeted Conjugation to a Scaffold Antibody. J Pharmacol Exp Ther 346:270-280.
8. Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, et al. (2012) betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 16:387-393.
9. Foltz IN, Hu S, King C, Wu X, Yang C, et al. (2012) Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci Transl Med 4:162ra153.
10. Veniant MM, Hale C, Helmering J, Chen MM, Stanislaus S, et al. (2012) FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One 7:e40164.
11. Yang C, Jin C, Li X, Wang F, McKeehan WL, et al. (2012) Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 7:e33870.
12. Holland WL, Adams AC, Brozinick JT, Bui HH, Miyauchi Y, et al. (2013) An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 17:790-797.
13. Lin Z, Tian H, Lam KS, Lin S, Hoo RC, et al. (2013) Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 17:779-789.
14. Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, et al. (2009) Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 297:E1105-1114.
15. Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, et al. (2008) FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity. FEBS Lett 582:1725-1730.
16. Reitman ML (2013) FGF21 mimetic shows therapeutic promise. Cell Metab 18:307-309.
17. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, et al. (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18:333-340.
18. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, et al. (2012) Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 122:1022-1036.
19. Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, et al. (2009) Different roles of N- and C-termini in the functional activity of FGF21. J Cell Physiol 219:227-234.
20. Yie J, Hecht R, Patel J, Stevens J, Wang W, et al. (2009) FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett 583:19-24.
21. Cernkovich ER, Deng J, Bond MC, Combs TP, Harp JB (2008) Adipose-specific disruption of signal transducer and activator of transcription 3 increases body weight and adiposity. Endocrinology 149:1581-1590.
22. Kim HW, Lee JE, Cha JJ, Hyun YY, Kim JE, et al. (2013) Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. Endocrinology 154:3366-3376.
23. Adams AC, Coskun T, Rovira AR, Schneider MA, Raches DW, et al. (2012) Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 7:e38438.
24. Adams AC, Cheng CC, Coskun T, Kharitonenkov A (2012) FGF21 requires betaklotho to act in vivo. PLoS One 7:e49977.
25. Chau MD, Gao J, Yang Q, Wu Z, Gromada J (2010) Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A 107:12553-12558.
26. Mulligan JD, Gonzalez AA, Stewart AM, Carey HV, Saupe KW (2007) Upregulation of AMPK during cold exposure occurs via distinct mechanisms in brown and white adipose tissue of the mouse. J Physiol 580:677-684.
27. Koh HJ, Hirshman MF, He H, Li Y, Manabe Y, et al. (2007) Adrenaline is a critical mediator of acute exercise-induced AMP-activated protein kinase activation in adipocytes. Biochem J 403:473-481.
28. Yie J, Wang W, Deng L, Tam LT, Stevens J, et al. (2012) Understanding the physical interactions in the FGF21/FGFR/beta-Klotho complex: structural requirements and implications in FGF21 signaling. Chem Biol Drug Des 79:398-410.
29. STANISLAUS S, Xu J, Ellison MM (2013) Method of treating or ameliorating type 1 diabetes using fgf21. Google Patents.
30. Muise ES, Souza S, Chi A, Tan Y, Zhao X, et al. (2013) Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21. PLoS One 8:e73011.
31. Owen BM, Ding X, Morgan DA, Coate KC, Bookout AL, et al. (2014) FGF21 Acts Centrally to Induce Sympathetic Nerve Activity, Energy Expenditure, and Weight Loss. Cell Metab.
32. Talukdar S, Oh da Y, Bandyopadhyay G, Li D, Xu J, et al. (2012) Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med 18:1407-1412.
33. Stokes MP, Farnsworth CL, Moritz A, Silva JC, Jia X, et al. (2012) PTMScan direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS. Mol Cell Proteomics 11:187-201.